Spero Therapeutics informa las ganancias trimestralmente. Estos informes de ganancias trimestrales ofrecen a los inversores una visión de los resultados financieros de una empresa durante un período de 3 meses. Los informes de ganancias casi siempre incluyen resultados de EPS e ingresos.
Analice el historial de beneficios de Spero Therapeutics utilizando filtros y clasificaciones avanzadas.
Get Alert | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
SPRO | Spero Therapeutics | -$0.32 | -$0.25 | — | — | $13.47M | — | — | — | 11/13/2025 | |
SPRO | Spero Therapeutics | -$0.33 | -$0.34 | -$0.03 | 91.18% | $10.20M | — | $14.19M | — | 08/12/2025 | |
SPRO | Spero Therapeutics | -$0.24 | -$0.55 | -$0.25 | 54.55% | $9.27M | $11.00M | $5.87M | -46.60% | 05/13/2025 | |
SPRO | Spero Therapeutics | $0.96 | -$0.31 | -$0.38 | -22.58% | $73.52M | $6.20M | $15.04M | 142.65% | 03/27/2025 | |
SPRO | Spero Therapeutics | -$0.06 | -$0.36 | -$0.32 | 11.11% | $25.47M | $7.67M | $13.47M | 75.61% | 11/14/2024 | |
SPRO | Spero Therapeutics | -$0.23 | -$0.38 | -$0.33 | 13.16% | $2.72M | $3.27M | $10.20M | 211.83% | 08/05/2024 | |
SPRO | Spero Therapeutics | -$0.25 | -$0.04 | -$0.24 | -500.00% | $2.07M | $21.53M | $9.27M | -56.96% | 05/15/2024 | |
SPRO | Spero Therapeutics | $0.55 | -$0.10 | $0.96 | 1060.00% | $47.44M | $18.63M | $73.52M | 294.65% | 03/13/2024 | |
SPRO | Spero Therapeutics | -$0.33 | -$0.03 | -$0.06 | -100.00% | $2.01M | $14.97M | $25.47M | 70.16% | 11/13/2023 | |
SPRO | Spero Therapeutics | -$0.51 | -$0.34 | -$0.23 | 32.35% | $1.99M | $1.07M | $2.72M | 153.83% | 08/10/2023 | |
SPRO | Spero Therapeutics | -$1.01 | -$0.33 | -$0.25 | 24.24% | $2.07M | $1.00M | $2.07M | 106.90% | 05/11/2023 | |
SPRO | Spero Therapeutics | -$0.90 | $0.04 | $0.55 | 1275.00% | $2.74M | $22.87M | $47.44M | 107.44% | 03/30/2023 | |
SPRO | Spero Therapeutics | -$0.70 | -$0.30 | -$0.33 | -10.00% | $3.06M | $5.42M | $2.01M | -62.99% | 11/14/2022 | |
SPRO | Spero Therapeutics | -$0.63 | -$0.54 | -$0.51 | 5.56% | $5.15M | $1.15M | $1.99M | 73.30% | 08/10/2022 | |
SPRO | Spero Therapeutics | -$0.66 | -$0.87 | -$1.01 | -16.09% | $7.30M | $2.57M | $2.07M | -19.49% | 05/16/2022 | |
SPRO | Spero Therapeutics | -$0.68 | -$0.75 | -$0.90 | -20.00% | $1.91M | $4.95M | $2.74M | -44.57% | 03/31/2022 | |
SPRO | Spero Therapeutics | -$0.86 | -$0.66 | -$0.70 | -6.06% | $4.00M | $4.47M | $3.06M | -31.45% | 11/10/2021 | |
SPRO | Spero Therapeutics | -$0.85 | -$0.77 | -$0.63 | 18.18% | $1.73M | $4.03M | $5.15M | 27.74% | 08/05/2021 | |
SPRO | Spero Therapeutics | -$1.22 | -$0.64 | -$0.66 | -3.12% | $1.70M | $3.16M | $7.30M | 131.01% | 05/06/2021 | |
SPRO | Spero Therapeutics | -$1.32 | -$0.74 | -$0.68 | 8.11% | $3.63M | $3.67M | $1.91M | -48.04% | 03/11/2021 | |
SPRO | Spero Therapeutics | -$0.95 | -$0.87 | -$0.86 | 1.15% | $4.64M | $3.20M | $4.00M | 24.84% | 11/05/2020 |
| Trimestre Fiscal | Fecha reportada | EPS real | EPS estimado | Sorpresa % |
|---|---|---|---|---|
| Q2 | 2025-08-12 | $-0.03 | $-0.34 | 91.2 % |
| Q1 | 2025-05-13 | $-0.25 | $-0.55 | 54.5 % |
| Q4 | 2025-03-27 | $-0.38 | $-0.31 | -22.6 % |
| Q3 | 2024-11-14 | $-0.32 | $-0.36 | 11.1 % |
| Trimestre Fiscal | Fecha reportada | Ingresos reales | Ingresos estimados | Sorpresa % |
|---|---|---|---|---|
| Q1 | 2025-05-13 | $5.87M | $11.00M | -46.6 % |
| Q4 | 2025-03-27 | $15.04M | $6.20M | 142.7 % |
| Q3 | 2024-11-14 | $13.47M | $7.67M | 75.6 % |
| Q2 | 2024-08-05 | $10.20M | $3.27M | 211.8 % |
Está previsto que Spero Therapeutics (SPRO) presente resultados el noviembre 13, 2025. Los últimos resultados se publicaron el agosto 12, 2025 para el Q2.
El BPA real fue de $-0.03, que superó la estimación de $-0.34.
Los ingresos reales fueron $14.2M, que superó la estimación de $0K.
Explora Estimaciones de beneficios, BPA e ingresos sobre todos los valores.